Search the Newsreel

Earnings Miss: Amdocs Limited Missed EPS By 59% And Analysts Are Revising Their Forecasts

Amdocs Limited announced its Q3 2024 earnings, missing analyst EPS estimates by 59% with reported earnings of US$0.40 per share against an expectation of US$0.97. Despite the earnings miss, revenue remained stable year-on-year at US$1.2 billion, and the company reaffirmed its full-year revenue growth …

Amdocs Limited Just Missed Earnings - But Analysts Have Updated Their Models

Amdocs Limited's shares rose 5.1% despite missing third-quarter statutory earnings estimates, though revenues were in line with predictions. Analysts have since updated their models, increasing their earnings per share estimates for 2027 to US$6.95, while revenue forecasts remain at US$4.85 billion. Despite the increased …

Oculis to Acquire Full Global Rights to Privosegtor from Accure Therapeutics in Strategic Asset Purchase

Oculis Holding AG announced a strategic asset purchase agreement to acquire the global development and commercial rights to Privosegtor and future candidate ACT-02 from Accure Therapeutics. This deal, valued at $3.8 million upfront cash and up to 2,050,000 Oculis ordinary shares, terminates their previous …

Oculis acquires full rights to Privosegtor, boosting its neuro-ophthalmology drug pipeline and cutting royalties.

Oculis Holding AG has acquired all worldwide rights to Privosegtor from Accure Therapeutics for an upfront cash payment of $3.8 million and up to 2,050,000 Oculis shares, with the deal expected to close by early 2027. This acquisition ends their previous license agreement and …

Oculis undirritar kaupsamning við Accure Therapeutics um leiðandi þróunarlyfið Privosegtor og eflir þannig stöðu Oculis sem leiðandi vaxtarfyrirtækis á sviði taugaaugnlækninga

ZUG, Sviss og BARSELÓNA, Spáni, ágúst 10, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” eða “félagið”), alþjóðlegt líftæknifyrirtæki með áherslu á nýsköpun til að mæta brýnni þörf fyrir meðferðir við augnsjúkdómum og augntaugasjúkdómum, og Accure Therapeutics, S.L. (“Accure”), rannsóknar- og …

Oculis Signs Asset Purchase Agreement with Accure Therapeutics for Lead Candidate, Privosegtor, Fortifying Oculis’ Position as an Emerging Leading Neuro-Ophthalmology Company

ZUG, Switzerland and BARCELONA, Spain, August 10, 2026 Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, and Accure Therapeutics, S.L. (“Accure”), a …

Infosys signs 10-year agreement with Crocs, to modernise global operations

Infosys has secured a decade-long strategic agreement with Crocs to modernize the footwear company's global operations. This collaboration will leverage Infosys' AI-first platforms to streamline Crocs' IT and business systems, aiming to reduce costs, enhance efficiency, and support scalable growth worldwide. Both companies emphasize …

Crocs (CROX) Is Up 6.7% After Earnings Beat And Larger Buybacks Authorization Has The Bull Case Changed?

Crocs, Inc. recently reported past second‑quarter 2026 results showing sales of US$1,179.47 million and net income of US$204.89 million, alongside upgraded full‑year guidance and an expanded share repurchase program that now totals US$5.21 billion in authorization. The combination of a swing from a very …

Crocs (CROX) Stock Could Be 34% Undervalued After Weak Q3 Outlook

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Crocs stock has delivered a strong 81.6% return over the past year, yet valuation checks and an intrinsic value estimate based on a Discounted Cash …

Crocs (NasdaqGS:CROX) Stock Price

This Simply Wall St article provides a detailed overview of Crocs (NasdaqGS:CROX) stock, including its market capitalization, share price performance, and various fair value narratives from different analysts and users. It also covers key financial details, recent news like insider transactions, and analyst commentary, …

Oculis Holding AG (OCS) stock price, news, quote and history

This article provides comprehensive financial information for Oculis Holding AG (OCS), including its current stock price, historical data, and key financial metrics. It highlights the company's focus on developing drug candidates for ophthalmic, neuro-ophthalmic, and neurological diseases, with lead products in various clinical trial …

Oculis (NASDAQ:OCS) Announces Quarterly Earnings Results

Amdocs (DOX) Stock Faces AI Promise And Sharply Lower EPS

Amdocs (DOX) stock saw little movement after its Q3 2026 earnings, despite a sharp 58% drop in basic EPS and a significant one-off loss. While revenue and non-GAAP operating margins remained stable, the company is heavily investing in AI, leading to a debate among …

Amdocs (NASDAQ:DOX) Releases Quarterly Earnings Results, Meets Estimates

Crocs (NASDAQ: CROX) insider plans $1.51M sale of 10,928 shares via Form 144

An insider at Crocs, Inc. (NASDAQ: CROX) plans to sell 10,928 shares of common stock, valued at approximately $1.51 million, through Morgan Stanley Smith Barney LLC on August 7, 2026. These shares originated from Performance Stock Units granted in 2021 and 2024 as compensation. …

Oculis Holding AG Stock 12‑Month Price Target Cut to $36.26, Implies 193% Upside

Analysts have lowered the 12-month average price target for Oculis Holding AG stock (OCS) to $36.26 from $36.49, with a range of $22.25 to $43.27. Despite the slight reduction, this new target still suggests a significant 193% potential upside from its Aug. 6 closing …

Amdocs Ltd (DOX) Stock Up 6.9% and Still Undervalued -- GF Score: 73/100

Amdocs Ltd (DOX) saw its shares rise by 6.9% to $59.12. GuruFocus assesses DOX as "Significantly Undervalued" with a 32.6% upside potential against its GF Value™ of $87.69, despite a current P/E of 14.1x being below its 5-year median. The company boasts a GF …

California State Teachers Retirement System Has $4.99 Million Stock Holdings in Crocs, Inc. $CROX

The California State Teachers Retirement System increased its stake in Crocs (NASDAQ:CROX) by 16.3% in the first quarter, now owning 60,066 shares valued at $4.99 million. Crocs reported strong quarterly earnings, beating estimates with $4.55 per share and revenue up 2.6% year-over-year, and provided …

Oculis Holding earnings beat by CHF0.23, revenue topped estimates

Oculis Holding reported second-quarter earnings that surpassed analyst estimates by CHF0.23, with revenue also exceeding expectations at CHF311.14K against a consensus of CHF157.82K. Despite the positive earnings surprise, the company's stock price has seen a significant decline, down -62.070% in the last 3 months …

Oculis Holding AG (OCS) Reports Q2 Loss, Tops Revenue Estimates

Oculis Holding AG (OCS) reported a narrower-than-expected Q2 loss of $0.2 per share, beating the Zacks Consensus Estimate of a $0.48 loss, and surpassed revenue estimates with $0.39 million. Despite this, the company's shares have fallen 39.6% year-to-date, contrasting with the S&P 500's gain, …

Amdocs Ltd Up Over 6%, On Pace For Largest Percent Increase Since May 2022 -- Data Talk

Amdocs Ltd (DOX) stock is currently up over 6%, positioning it for its largest percentage increase since May 2022. The trading volume today has significantly surpassed its 50-day average. This surge follows the company's fiscal third-quarter results which included raising its full-year earnings forecast.

Crocs, Inc. (CROX) CEO exercises 200,000 options, 105,610 withheld

Crocs, Inc. CEO Andrew Rees exercised 200,000 employee stock options at $6.98 per share on August 4, 2026, receiving 200,000 common shares. The company withheld 105,610 shares at $141.19 each to cover exercise and tax obligations. Rees's family trust holds an additional 743,293 shares, …

Oculis birtir uppgjör fyrir annan ársfjórðung 2026 og kynnir áfanga í rekstri félagsins

ZUG, Sviss, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Félagið færir nú áherslur sínar yfir á taugaauknlækningar með Privosegtor sem leiðandi þróunarlyf félagsins á síðari stigum klínískrar þróunar í gegnum PIONEER-áætlunina. Í kjölfar jákvæðs pre-IND fundar við Matvæla- og lyfjaeftirlit Bandaríkjanna (FDA), eru möguleikar á …

Oculis Reports Q2 2026 Financial Results and Provides Company Update

Oculis, a global biopharmaceutical company, announced its Q2 2026 financial results, reporting $282.3 million in cash, cash equivalents, and short-term investments, providing a cash runway into the second half of 2029. The company is advancing its neuro-ophthalmology pivot with Privosegtor as a lead late-stage …

Amdocs (DOX) insider plans $1.86M sale of 33,584 shares after prior disposals

Amdocs Limited insider Tamar Rappaport Dagim plans to sell 33,584 ordinary shares worth approximately $1.86 million through Oppenheimer & Co. Inc. These shares were acquired on November 11, 2023, through the vesting of RSUs without cash consideration. The filing also discloses prior sales by …

Amdocs Limited 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:DOX) 2026-08-06

Amdocs Limited (NASDAQ:DOX) released its Q3 2026 earnings call presentation, following a quarter where its EPS of $1.84 missed estimates by $0.00, but revenue of $1.17 billion, up 2.66% year-over-year, beat expectations by $1.63 million. The company's slide deck provides further details on these …

Amdocs Q3 Earnings Meet Estimates as Managed Services Hit Record

Amdocs Limited DOX reported third-quarter fiscal 2026 non-GAAP earnings of $1.84 per share, which increased 7% on a year-over-year basis. The figure matched the Zacks Consensus Estimate. Amdocs' fiscal third-quarter revenues of $1.175 billion missed the consensus mark by 0.04%. The top line increased …

FMR LLC discloses 7.1% Crocs (CROX) stake totaling 3.51M shares

FMR LLC and Abigail P. Johnson have reported a beneficial ownership of 7.1% in Crocs, Inc., amounting to 3,507,502 shares of common stock as of June 30, 2026. FMR LLC holds sole voting power over 3,362,891.33 shares and sole dispositive power over all 3,507,502 …

FMR LLC and Abigail P. Johnson disclose 9.4% Amdocs Limited (DOX) ownership

FMR LLC and Abigail P. Johnson have reported beneficial ownership of 9.4% of Amdocs Limited's common stock, totaling 10,032,312.93 shares. FMR LLC holds sole voting power over 8,783,014.17 shares and sole dispositive power over all 10,032,312.93 shares, while Abigail P. Johnson also has sole …

Optimum Transforms Customer Bill Experience with AI-Enhanced Platform Powered by Amdocs aOS Cognitive Core

Optimum has launched a redesigned customer billing experience, powered by Amdocs Bill Experience and Amdocs' aOS Cognitive Core, to provide greater transparency and self-service. The new platform uses AI-driven automation to simplify bills with clearer explanations, visual insights, and proactive bill guidance, aiming to …

Will Amdocs' (DOX) 10-Year Liberty Latin America AI Deal Offset Weaker Q3 Profitability?

Amdocs Limited reported mixed Q3 2026 results with revenue growth but a significant drop in net income and diluted EPS. Despite this, the company secured a 10-year AI-enabled modernization deal with Liberty Latin America and other projects, highlighting a growing pipeline in AI and …

Amdocs (NASDAQ: DOX) Q3 2026: agentic strategy, Liberty deal, GAAP cut

Amdocs (NASDAQ: DOX) reported Q3 fiscal 2026 revenue of $1.175 billion and non-GAAP diluted EPS of $1.84. The company announced a new 10-year partnership with Liberty Latin America, leveraging its "agentic" growth strategy and aOS Agentic Telco Operating System. While non-GAAP EPS guidance for …

Amdocs (DOX) Stock Looks Undervalued After A 36% Fall

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Amdocs stock has fallen 35.7% over the past year, yet the broader valuation checks still lean cheap, which raises a clear question about how …

A1 Austria Completes Billing, Charging and Catalog Transformation with Amdocs

Amdocs announced that A1 Austria has successfully completed a multi-year transformation of its monetization environment, deploying Amdocs Charging, Billing, and Catalog. This modernization, with components on Microsoft Azure, aims to simplify operations, improve performance, and enable future growth by streamlining processes and reducing costs. …

Amdocs (DOX) Releases Q3 2026 Earnings: Revenue Growth but Profit Declines

Lumen Extends Multi-Cloud Strategy with Amdocs, Modernizing Enterprise Service Orchestration

Lumen Technologies is expanding its multi-cloud strategy by collaborating with Amdocs to modernize its enterprise service orchestration and order management platform on Amazon Web Services (AWS). This initiative builds on previous migrations to Google Cloud and Microsoft Azure, aiming to create a resilient, cloud-native …